Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy

Molecular Imaging and Biology

Volumn 8, Issue 1, 2006, Pages 36-42

  Pio, Betty S ^a   Park, Cecilia K ^a   Pietras, Richard ^a   Hsueh, Wei Ann ^a   Satyamurthy, Nagichettiar ^a   Pegram, Mark D ^a   Czernin, Johannes ^a   Phelps, Michael E ^a   Silverman, Daniel H S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; FLT; Fluorothymidine; PET; Positron emission tomography; Therapy response

Indexed keywords

3' FLUOROTHYMIDINE; CA 27-29 ANTIGEN; CAPECITABINE; CYTOTOXIC AGENT; DOCETAXEL; EXEMESTANE; FLUORODEOXYGLUCOSE F 18; TRASTUZUMAB; TUMOR MARKER; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION FUNCTION; DISEASE COURSE; DRUG EFFICACY; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER METASTASIS; METASTASIS POTENTIAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TIME SERIES ANALYSIS; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY SCINTISCANNING; ADULT; BREAST TUMOR; COMPARATIVE STUDY; DRUG EFFECT; FOLLOW UP; METABOLISM; METASTASIS; MIDDLE AGED; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SCINTISCANNING;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIDEOXYNUCLEOSIDES; FEMALE; FLUORINE RADIOISOTOPES; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TUMOR BURDEN;

EID: 33645826040     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-005-0029-9     Document Type: Article

References (22)

1. Shields AF, Grierson JR, Dohmen BM, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336
2. 76Br-BFU as proliferation markers. J Nucl Med 43:1688-1698
3. 18F]FLT uptake after chemotherapy: An experimental study. Eur J Nucl Med 29:1462-1469
4. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8:3315-3323
5. 18F]-FLT) as positron emission tomography tracer for imaging proliferation is a murine B-cell lymphoma model and in the human disease. Cancer Res 63:2681-2687
6. 18F]fluorothymidine for imaging of primary breast cancer: A pilot study. Eur J Nucl Med Mol Imaging 31:720-724
7. Dittman H, Dohman BM, Paulsen F, et al. (2003) [(18)F]FLT PET for diagnosis and staging of thoracic tumors. Eur J Nucl Med Mol Imaging 30:1407-1412
8. 18F-fluoro-d-glucose. Mol Imaging Biol 4:65-70
9. 18F]FLT preparation. J Radioanal Nucl Chem 251:55-58
10. 18F]FLT). J Radioanal Nucl Chem 243:843-846
11. Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151-1159
12. Huovinen R, Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M (1993) Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 67:787-791
13. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ (1996) Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2:933-939
14. Schirrmeister H, Guhlmann A, Kotzerke J, et al. (1999) Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 17:2381-2389
15. Beaney RP, Lammertsma AA, Jones T, McKenzie CG, Halnan KE (1994) Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1:131-134
16. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T (1992) Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method. Cancer Res 52:1592-1597
17. 18F-fluorocyclophosphamide), a potential tracer for breast tumor prognostic imaging with PET. J Label Compd Radiopharm 48:635-643
18. Kesner AL, Townsend A, Hsueh WA, et al. (2004) A non-invasive assay to predict chemotherapy response to 5-fluorouracil using [18F]-5-FU and PET. J Nucl Med 45:331P, (Abstract)
19. Hsueh WA, Gangloff A, Kesner AL, et al. (2004) Predicting chemotherapy response to paclitaxel using [18F]-fluoropaclitaxel and PET. J Nucl Med 45:38P, (Abstract)
20. 18F]-fluoropaclitaxel beyond tumor size as a predictor for paclitaxel resistance. J Nucl Med 46(S2):398P, (Abstract)
21. Hsueh WA, Gangloff A, Kesner AL, Beryt MM, Pegram M, Czernin J, Phelps ME, Silverman DH (2005) FDG and FLT microPET predictors of tumor response and survival following chemotherapy. J Nucl Med 46(S2):155P, (Abstract)
22. 18F]-fluoropaclitaxel. J Nucl Med 46(11):1866-1871